DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist

Information source: AZ Jan Palfijn Gent
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infertility

Intervention: Decapeptyl Daily (Drug); pregnyl (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: AZ Jan Palfijn Gent

Official(s) and/or principal investigator(s):
Wim Decleer, gynacologist, Principal Investigator, Affiliation: IVF Centrum Jan Palfijn Gent

Summary

The purpose of this study is to see whether patients triggered with only human Chorion Gonadotropin (hCG) have higher number of Metaphase II oocytes (MII) and implantation rate than patients triggered with hCG combined with Gonadotropin Releasing Hormone (GnRH) agonist.

Clinical Details

Official title: Randomised Controlled Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: MII Oocytes

Secondary outcome:

Pregnancy Rate

Patients With Cryopreserved Embryos

Eligibility

Minimum age: N/A. Maximum age: 38 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Intra-cytoplasmic sperm injection (ICSI) patients below 38 years

- 1,2 or 3 rd IVF-cycle

Exclusion Criteria:

- polycystic ovary syndrome (PCOS) patients

- patients with endocrinological diseases or problems

Locations and Contacts

A Z Jan Palfijn, Gent, Oost-vlaanderen 9000, Belgium
Additional Information

Starting date: November 2011
Last updated: February 3, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017